Focusing on Late-Stage and Commercial Biotech

Jonathan advises favoring late-stage and commercial-stage companies with clear paths to market and discusses rare disease regulatory tailwinds.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!